Prokarium is developing Vesibax, an innovative, safe, and effective microbial immunotherapy (MI) for early-stage bladder cancer, a disease with afflicts over 550,000 individuals globally every year. CEO Ted Fjallman to learn more about Prokarium’s upcoming pipeline of novel therapies, its current focus, and recent funding round from investors that include Korea Investment Partners (KIP), Flerie Invest, Riyadh Valley Company (RVC), and the UK Government’s Future Fund.
Pitch decks come in a lot of flavors. We’ve seen five pages, we’ve seen fifty. We’ve seen them sparsely punctured with bullet points, we’ve seen what might have happened if David Foster Wallace wrote a novel in PowerPoint. Where’s the golden mean? What can you throw away and what sparks joy?